Questions concerning fertility preservation during transition in girls with Turner syndrome – review of the literature

Małgorzata Więcek¹, Jakub Gawlik², Zuzanna Nowak², Aneta Gawlik¹*

¹Department of Pediatrics and Pediatric Endocrinology, Faculty of Medical Sciences, Medical University of Silesia, Katowice, Poland

²Student Scientific Society at the Department of Pathophysiology, Jagiellonian University Medical College, Krakow, Poland

*Correspondence:
Aneta Gawlik
Department of Pediatrics and Pediatric Endocrinology
Medical University of Silesia
40-752 Katowice, ul. Medykow 16, Poland
agawlik@sum.edu.pl

Short title: Fertility preservation in Turner syndrome.

Keywords: Turner Syndrome; Fertility Preservation; ovarian reserve; cardiovascular risk.

Word count: 4661
Abstract

Loss of fertility is one of the most important concerns facing Turner Syndrome (TS) patients as they transition into adult healthcare. Due to the limited and rapidly decreasing ovarian reserve many TS patients require fertility preservation (FP) techniques to preserve their reproductive potential until they are ready to pursue procreation. One has to also remember about the additional risks connected with pregnancy in TS patients. In order to determine the optimal time for introducing FP techniques and decrease the chance of an unnecessary intervention, markers and procedures assessing ovarian reserve have been developed. The exposure to potential cardiovascular complications should be determined before FP to avoid unnecessary procedures in patients with potential contraindications to pregnancy. The aim of the present review is to answer the following three questions important for successful preservation of fertility and safe pregnancy in TS. Which markers of ovarian reserve should be used as selection criteria for FP? Which methods of FP are the safest and most effective? If are there any cardiovascular contraindications to fertility preservation? For each of those questions separate literature searches have been conducted. A total of 86 articles have been included in this review, 34 for the first question, 35 for the second and 17 for the third. Ovarian reserve markers and cardiovascular contraindications to pregnancy should be established before FP, however there are no unambiguous indicators which patients should be disqualified from the FP and more evidence is needed in this subject.

1. Introduction

Turner syndrome (TS) is the most common sex chromosomal abnormality found in females, with the prevalence of about 1 in 2000 to 1 in 2500 live female births (1). It is a result of a partial or complete loss of one of the X chromosomes and depending on the level of mosaicism (the proportion of affected cells to healthy ones) it can vary in severity (2). Short
stature and primary ovarian failure (POI) are the hallmarks of TS, while it can also manifest with cardiac and renal anomalies, autoimmune disorders, and hearing loss (2). Infertility is reported as one of the most important concerns facing TS patients (3), as only about 5% will ever experience spontaneous pregnancy (4,5). Alongside puberty induction and cardiovascular status, fertility preservation is one of the most important issues during the transition process in TS. With the advent of assisted reproductive technologies (ART) medicine brought new hope for these patients. However due to the limited and rapidly decreasing ovarian reserve many of them won’t be able to benefit from ART upon reaching adulthood. Fertility preservation (FP) techniques, such as cryopreservation of oocytes or ovarian tissue, introduced at a young age are thus essential in giving these patients a chance at reproduction and parenthood.

As FP techniques are invasive and may cause complications, they should be introduced only when tangible benefit is possible. That is why a number of markers and procedures have been developed to properly assess the ovarian reserve, before attempting FP (6,7). ART should also be applied with caution, as pregnancy may carry serious risks for TS women. Therefore, the exposure for potential cardiovascular complications should also be determined before the FP to avoid unnecessary procedures in patients with contraindications to pregnancy (2).

The aim of this paper is to sum up the recent literature concerning fertility preservation in Turner Syndrome and to establish which factors should be taken in the consideration during preparation for the FP procedures.

2. Material and methods

In our study we set out to answer three questions important for successful preservation of fertility and safe pregnancy in TS. For each of those questions separate literature searches
have been conducted. Articles have been acquired from PubMed and Embase databases, based on keyword searches (described in detail for each question below), as well as selection criteria, which included: publication date between January 2002 and July 2022, written in English, published in a scholarly peer-reviewed journal. Additional sources were collected from reference lists found in aforementioned articles.

2.1. **Which markers of ovarian reserve should be used as selection criteria for FP?**

Keywords for this question included: “Turner Syndrome”, “Fertility Preservation”, “Ovarian Reserve”, “Mosaicism”, “FSH”, “Anti-Mullerian Hormone”, “Inhibins”.

2.2. **Which methods of FP are the safest and most effective?**

Keywords included: “Turner Syndrome”, “Fertility Preservation”, “Oocyte Cryopreservation”, “Ovarian Tissue Cryopreservation”, “Embryo Cryopreservation”.

2.3. **If are there any cardiovascular contraindications to fertility preservation?**

Keywords included: “Turner syndrome”, “Pregnancy Outcome”.

3. **Results**

86 articles were included in this review. Detailed selection process for each question has been presented on flowcharts (Fig.1-3).

3.1. **Which markers of ovarian reserve should be used as selection criteria for FP?**

Thirty-four articles were used in the preparation of this section (Fig. 1).

3.2. **Which methods of FP are the safest and most effective?**

Thirty-five studies were included in this section (Fig. 2).
3.3. If are there any cardiovascular contraindications to fertility preservation?

Due to finding a sufficient number of original research papers, case reports were excluded from this literature search. Seventeen articles concerning pregnancy outcomes in women with TS were included in this section (Fig.3). Numbers of TS patients, pregnancies, AoD and the rate of cardiac screening before pregnancy were systematized and presented in Table 1. Table 2 shows the characteristics of women diagnosed with AoD.

4. Discussion

4.1. Which markers of ovarian reserve should be used as selection criteria for FP?

Accelerated follicular depletion and gonadal dysgenesis are the primary characteristics of Turner Syndrome (TS) (5). Although the initial migration of primordial germline cells does not seem to be impaired, patients with TS experience a steep loss of germ cells, with oocyte reserves depleted even in early childhood (7). FP procedures are invasive and come with a certain risk of complications (2), therefore we should strive for efficient and accurate methods to properly assess the reserve before they are implemented. Below we analyse the currently available markers and procedures.

4.1.1. Karyotype

Patients diagnosed with mosaicism often present with milder TS stigmata and fewer characteristic pathologies. Generally, mosaic patients (either with 45,X/46,XX or 45,X/47,XXX) more frequently present with spontaneous and cyclical menstruation (8). It is believed that the quantity of oocytes and ovarian function is determined by the degree of mosaicism (proportion of 46, XX cells) in the ovaries (9), with women who have a higher proportion of the 46, XX line achieving more viable oocytes (10) and experiencing ovarian failure (OF) later in life (11). In a study examining 328 TS patients of various karyotypes, Noordman et al. determined that gonadal dysfunction was the most favourable in 45,X/46,XX
mosaic karyotypes in terms of spontaneous puberty (12). Additionally, 70% of the spontaneous pregnancies, seen in 2-5% of the TS population, are observed in 45,X/46,XX mosaic patients (4). Finally in a study by Borgström et al. 45,X/46,XX mosaicism has been determined as the best predictive factor for finding remaining follicles in the ovaries of girls with TS in terms of sensitivity (13). It is however worth to mention that even in non-mosaic TS girls primordial and primary follicles have been observed up to the age of 13 (10) and viable oocytes collection has been documented (14). This phenomenon could be explained by the “cryptic mosaicism” theory (15,16), which states that all surviving TS embryos diagnosed as non-mosaic 45,X, are actually mosaics for a “rescue line” that includes a viable karyotype. Reports show that even in cases when 45,X karyotype is confirmed in lymphocytes, buccal cells, and urine cells, cryptic mosaicism can still be present in ovarian tissue (17). Taking that into consideration we propose that non-mosaic karyotype should be treated as a factor negatively affecting chances for finding viable oocytes, but not an absolute contraindication for FP.

4.1.2. Age

Studies show that the initial migration of germline cells to the genital ridges is undisturbed in TS foetuses (18) and germ cells can be found in ovaries <25th gestational week (GW) (19). Their steep loss is however observed as they enter the early stage of meiotic prophase (20), around the second and third trimesters. Comparing to age-matched controls at 20 GW the proportion of apoptotic oocytes is markedly higher in TS, reaching even 70% in TS and only 7% in controls (21). This results in a drastically decreased number of germ cells even in the prenatal stage. Additionally, the formation of primordial follicles is often impaired and instead replaced by connective tissue proliferation (19). Total depletion of the oocyte reserve can be already observed in the first years of life in some non-mosaic patients. A recent study asserting the connection between OF and karyotype showed that the median age of OF was
10 years in 45,X patients, with 100% of this karyotype succumbing to OF. In contrast only 1 out of 13 studied patients with 45,X/46,XX mosaicism (mean 10 years of age) suffered from OF, which was however diagnosed at the age of 4. This study has also established a negative correlation between the proportion of 45,X cells in the peripheral karyotype and age of OF (11).

Assuming a mean age of diagnosis of TS at about 5-7 years of age, this leaves a very limited amount of time to consider FP. In order to ensure the best outcomes this topic should be discussed as soon as possible after the diagnosis, even in infancy. In mosaic patients this window of opportunity may be wider, although one cannot forget about possible discrepancies between peripheral and oocyte karyotype determination, which could be responsible for earlier OF in these patients.

4.1.3. FSH

Follicle-stimulating hormone (FSH) has been shown to display a biphasic pattern of secretion in TS population independent of studied karyotype (22–25). It remains elevated from birth to around the age of 5, when it drops to pre-pubertal levels, and increases again at the age of 10, reaching postmenopausal levels a few years later. While the same pattern is observed in healthy girls, there are some clear differences. Most studies agree that in TS patients who suffered from the most severe ovarian failure FSH levels are markedly increased during infancy and at the time of expected puberty (23). Ages 5-10 however are a point of contention, with earlier publications stating that FSH levels recorded during this time are not elevated compared to pre-pubertal healthy girls (23,24), while some recent studies using ultrasensitive assays claim that the FSH decline after the age of 5 doesn’t in fact reach normal levels and could be used to diagnose girls with unexplained short stature (22). Nevertheless, diagnosis of ovarian failure based on FSH levels can be made only before the age of 5 and in
adolescence. Taking into account that with the advent of ovarian tissue cryopreservation midchildhood could become a vital time for FP, this poses as a considerable obstacle for using FSH as a viable marker.

Scarce information on the relation between presence of available oocytes and FSH in TS is available, with most studies describing the adolescent and adult TS populations. In a study by Borgstrom et al. FSH within normal levels for age and stage of puberty predicted the presence of follicles obtained during laparoscopic biopsy with accuracy of 73%, FSH<11 mIU/ml was characterized with 69% sensitivity (second highest sensitivity after mosaic karyotype) and FSH>15 mIU/ml displayed 77% specificity (13). Based on analysis of cases of oocyte cryopreservation by Schleedoorn, we can however see that in 8 out of 18 recorded instances of successful oocyte retrieval, FSH before ovaria stimulation was above >15 mIU/ml. Better results are achieved when FSH is combined with other factors, as is shown in a retrospective study by Volodarsky-Perel (26). Combining FSH ≤ 20mIU/ml with AMH > 0.16ng/mL and ultrasonographic finding of ≥ 1 antral follicle yielded a 100% success rate of finding follicles in OTCP, if ≥2 parameters were positive.

Even though presently we lack sufficient results that would link FSH concentrations with follicle count, a number of longitudinal studies are on the horizon that could shed light on this topic (27,28).

4.1.4. AMH

Anti-Mullerian hormone is secreted by the granulosa cells of preantral follicles in the process of determining the dominant follicle. It has been closely studied in general population with regards to predicting follicular reserve and follicle recruitment (29) and correlates well with antral follicle count in adults (30) and adolescents (31). In younger paediatric patients reports on this correlation are however inconclusive, with some studies reporting positive correlation
(32) and some none (33,34). In TS AMH concentrations are higher in patients with spontaneous puberty and mosaic karyotype (35,36). In a study of TS patients by Borgstrom et al. AMH concentrations above 2 pmol/l (0.28 ng/ml) (accepted norm for teenagers) predicted the presence of follicles in laparoscopic biopsy with accuracy of 81%, sensitivity of 64% and specificity of 88% (20). Other studies also used this cut-off point as an indication for oocyte (14) or ovarian tissue cryopreservation (26) with good results. However, the low sensitivity makes this marker prone to omission of viable patients, that’s why repeated measurements alongside other markers are recommended.

In recent years AMH has emerged as the dominant marker determining the feasibility of FP. In recommendations by Oktay et al. decrease of AMH <2 ng/ml (14.28 pmol/l) in prepubertal girls is an indication for OTC (6), while in recommendations by Nawroth et al. AMH plays an even more prominent role, with AMH <0.5 ng/ml (3.57 pmol/l) being a contraindication for cryopreservation in non-mosaic patients (37).

4.1.5. Inhibin B

Inhibin B is produced by small developing follicles and thus has been proposed as a marker of ovarian reserve. Its’ concentration decreases earlier than any other marker of ovarian reserve and is more specific to decline in follicle number than inhibin A (38). Detectable levels of Inhibin B are present in prepubertal girls (at a detection limit of 20 pg/ml), in contrast to most adolescent TS patients without ovarian function (39). In a longitudinal study by Hagen et al. undetectable inhibin B in all measurements throughout childhood predicted premature ovarian failure in 20/20 patients and at least one detectable measurement has been recorded in 9/10 with spontaneous puberty (23). This shows that repeatable inhibin b measurements could be useful in predicting the condition of ovarian reserve, however
isolated undetectable concentrations are not an absolute contraindication for FP. No studies are currently available directly correlating inhibin b concentrations with follicle count.

4.1.6. Atrial follicle count

Atrial follicle count (AFC) is an imaging technique which can be performed using transabdominal, or transvaginal ultrasonography and MRI. The technique for performing AFC should be determined based on the patients age and feasibility of examination, as effectiveness seems to be comparable. AFC has shown a strong positive correlation with AMH among healthy adolescent girls (31,40), with some studies suggesting it’s interchangeability. However, when considering FP, especially in younger patients with non-mosaic karyotypes, AFC could provide invaluable first-hand information on the state of the ovarian reserve.

4.2. Which methods of FP are safest and most effective?

As previously mentioned, in most women with TS a decline in ovarian function before reaching reproductive age is observed. Taking into account the limited and ever-diminishing ovarian reserve in TS, breaching the topic of FP, evaluating ovarian reserve markers and proposing adequate FP procedures should be of upmost importance.

The main issue limiting the implementation of FP techniques is markedly reduced follicle pool, which can be depleted as soon as in pre-pubertal age (41,42). As a consequence, it is advised to assess ovarian reserve at the time of diagnosis and, if necessary, quickly introduce FP techniques due to accelerated ovarian aging and considerable risk of POF (43). Non-mosaic karyotype is considered as a factor negatively affecting chances for finding viable oocytes in TS patients, but not an absolute contraindication for FP. Accordingly, in this group it is advised to preserve ovarian tissue as early as possible, even in infancy (7). Mosaic
patients are believed to have spontaneous and cyclical menstruation (8), more viable oocytes (10) and experience ovarian failure (OF) later in life (11). Therefore, 45,X/46,XX mosaic patients are in most cases advised to postpone FP procedures until menarche with a greater chance of succeeding (6,7).

It is worth to remember that any implementation of FP techniques requires evaluation of the patients emotional and physical readiness (44). Additionally, contradictions and risks connected with pregnancy should be discussed, so that an informed decision could be made by the patient or their parent (45).

Currently, only two well-established FP techniques for TS patients with preserved ovarian function are available: oocyte cryopreservation (OC) and embryo cryopreservation (EC). Another experimental technique is being introduced into clinical practice - ovarian tissue cryopreservation (OTC), applicable in prepubertal girls.

Women with exhausted ovarian reserve can be offered other options, which include in vitro fertilization with donor oocytes (IVF-DO), gestational surrogacy (GS) and adoption.

Below we will focus on techniques which allow for conception of biological offspring, as adoption, oocyte donation or surrogacy are regulated by each country’s individual law, analysis of which goes beyond the scope of this paper.

4.2.1. Oocyte cryopreservation (OC)

Oocyte cryopreservation is considered to be a safe and effective technique of FP in women with mosaic TS (46,47). It is dedicated for post-menarchal girls with normal ovarian function, as it requires gonadotropin stimulation (7). Additionally, it’s feasibility before menarche is limited because of physical, sexual or psychosocial immaturity (48). Recently however, a case report by Azem at al. has been published describing a successful retrieval and
cryobanking of oocytes in a 7-year-old prepubertal TS patient (49). This could provide an alternative for OTC in younger TS patients.

Following the stimulation, ovarian response is monitored with the use of transabdominal ultrasound and serum oestradiol levels (48). Finally, oocyte retrieval is performed transvaginally under general anaesthesia. Transabdominal retrieval is feasible, but not recommended (50). In vitro maturation (IVM) is used to increase the yield of mature oocytes. Oocytes are then vitrified, which increases the post thaw survival (even to 90-95%), comparing to slow-freezing (9,51). Vitrified oocytes show similar fertilization and pregnancy rates comparing to fresh oocytes (51). Due to small yields in TS women, additional stimulations cycles are often required for a minimal number of 10 mature oocytes (50). DuoStim, which consists of two cycles of stimulation and oocyte retrieval, could also be used to maximize the yields in TS patients. In a case reported by Ito et al. using DuoStim, 10 and 9 oocytes were retrieved after two stimulation phases during one cycle, approximately doubling the yield (52).

The method also allows for preimplantation genetic screening, which is important in TS patients, in order to screen out aneuploidic embryos (53).

In patients with preserved menstrual cycles natural-cycle IVF is available. It is believed that oocytes retrieved from natural cycles might be of better quality and result in a healthier embryo (9) However, it prolongs the process of oocyte retrieval, which may be contraindicated in women with quickly diminishing ovarian function.

In a study by Oktay et al. oocyte stimulation has been performed in three girls with mosaic TS. After an average of 11 days for ovarian stimulation between 7-19 oocytes were retrieved, 53% were mature. IVM yielded 1 additional oocyte in one case and 5 in another. In one case
the procedure had to be repeated due to small number of vitrified mature oocytes. No complications were described.

In another study by Talaulikar et al. oocyte cryopreservation has been performed in 7 women with TS (only one non-mosaic patient). Oocyte retrieval was successful in all women, with a mean of 9 oocytes preserved, which was comparable to data from healthy women (46). As in the previous study no complications were reported.

While the first pregnancy from OC was recorded as far back as in 1986 (54), only very recently we have seen the first TS pregnancy (55). Cryopreservation of 29 oocytes was performed in a mosaic (45,X/46,XX) 25-year-old patient. Post thaw 23 oocytes survived (79.3%) and 13 were fertilized, resulting in 3 good quality blastocysts, 2 of which were euploid. One was transferred to the uterus, resulting in a healthy live birth. It is however worth to mention that 5 years before IVF the patient conceived spontaneously and gave birth to a healthy child.

4.2.2. Embryo cryopreservation (EC)

Although effective and well established in general population, this method is less frequently performed in TS patients, who usually necessitate FP techniques at a young age, as it requires a sperm donor or a partner. It follows the steps described in OC up to the point of oocyte retrieval (7). The success rate of EC appears to be greater than in OC, however this difference is negligible in younger patients (56).

In Turner syndrome pre-implantation genetic screening of the embryo is advised (57). Additionally, only one embryo should be implanted due to risks connected with pregnancy in TS (58).

Unfortunately, no reports of EC or pregnancies as a result of EC in TS patients have been found.
4.2.3. Ovarian Tissue Cryopreservation (OTC)

OTC is a new and emerging method, which allows for FP in prepubertal girls who cannot wait for OC or EC. This makes it an appealing choice for TS patients, especially those with non-mosaic karyotype or with markedly reduced oocyte reserve in young age. Additionally, it is the only method which allows for preservation of both fertility and endocrine function (9). A panel of international experts in 2020 agreed that OTC should be offered to TS patients, but only in a safe and controlled research setting (59).

The procedure involves laparoscopic removal of a part or a whole ovary, cryopreservation of the ovarian cortex, and subsequent auto-transplantation when the patient wants to pursue procreation. Transplantation can be orthotopic, which can even lead to a spontaneous pregnancy, or heterotopic, to subcutaneous tissue of the abdominal wall, forearm, and chest wall (60). Recent introduction of robot-assisted surgery and use of extracellular matrix scaffolds (AlloDerm) might lead to improvements in outcomes (61).

The effectiveness of OTC in TS patients might however be diminished due to the decreased ovarian reserve even in younger ages. To ensure the best outcomes a whole ovary should be removed, as to preserve as much follicles as possible (7,9). Additionally, as the cryopreservation of the ovarian cortex only preserves the primordial and primary follicles, integrated oocyte aspiration from antral follicles followed by IVM and OC should be used as a supplementary FP technique (43,62,63). Finally, to mitigate the oocyte loss connected with hypoxia during transplantation, vasculogenic factors, like S-1-P, VEGF or stromal cell enriched in CD34, could prove useful, although their clinical applicability is still being tested (50,64,65).

One has to remember about the disadvantages of OTC. As it involves two surgical interventions, it is characterized with greater risk for the patient, than both OC and EC (47).
Furthermore, the removal of the ovary for cryopreservation could also decrease chances of spontaneous puberty or accelerate ovarian failure (40). Nevertheless, for many patients with TS it could be the only viable option of FP.

The first case of OTC in TS patient has been described in 2008 by Huang et al. (66), and in 2019 Mamsen et al. reported the outcomes of OTC in 15 girls with TS, 4 non-mosaic, 12 prepubertal, ages 5 – 22.4 years. Oocytes were found in 9 girls, of whom only one was non-mosaic at 5 years of age. Most ovaries (6/9) showed a high rate of abnormal follicle morphology. In one mosaic patient IVM has been performed with 19% success rate, which, while lower than in general population, illustrates that TS oocytes from removed ovarian tissue can reach reproductive potential (67).

Although no pregnancies after OTC in TS patients have been reported, the ever-increasing number of live births from OTC in general population corroborates its effectiveness (68). In 2015 Demestre et. al described a case of pregnancy in a 27-year-old woman, after transplanting cryopreserved ovarian tissue, which was removed at the age of 13, before menarche (55). It was the first reported pregnancy from OTC performed before puberty, which is promising for TS patients from whom ovarian tissue has been harvested at a young age.

A deeper dive into the effectiveness of OCT in TS can be expected upon the publication of an ongoing long-term observational cohort study “PROTOCOL” (27).

4.3. If are there any contraindications to fertility preservation?

Congenital and acquired cardiovascular diseases are directly related to an increased mortality and morbidity incidence in patients with TS (69,70). Congenital heart defects affect 20–50% of patients with TS. Bicuspid aortic valve (BAV) is observed in approximately 30% of cases,
while coarctation of the aorta (CoA) in 7–18% of cases (70). Aortic dilatation occurs in 20-
25% of patients with TS and it can lead to aortic dissection (AoD) which is the most serious
cardiovascular complication, with mortality ratio reaching 58% (71,72). Aortic dilatation
tends to occur more frequently in patients with structural heart anomalies (BAV, CoA,
elongated transverse aorta) and hypertension (73). Due to reduced final height in TS women,
aortic diameter should be corrected by body surface area. TS-specific Z-score of <2.5 for
patients younger than 16 years old or aortic size index (ASI) <2.0 cm/m² in patients older
than 16 years old is considered normal aortic size (2).

A special condition affecting development of severe cardiovascular system complications is
pregnancy. Current guidelines by Gravholt et al. suggest that in case of serious aortic
dilatation (an ascending ASI of >2.5 cm/m²) or an ascending ASI 2.0–2.5 cm/m² with
associated risk factors for aortic AoD (including BAV, CoA, elongated transverse aorta and
hypertension) ART or spontaneous conception should be avoided (2). Those
recommendations are consistent with American Heart Association (AHA) statement from
2018 (74). American Society for Reproductive Medicine states that every significant heart
abnormality or ASI > 2cm/m² is an absolute contraindication to pregnancy (75).

Literature analysis was performed to show the prevalence of AoD in pregnant TS women and
describe characteristic of patients in which AoD occurred. This data can be helpful in
determining the eligibility for FP, when the decision about the invasive procedure in very
young age should be made after excluding the high risk of pregnancy. Current opinion on
pregnancy in TS women is based on the study from 2003. Karnis estimated the prevalence of
AoD among pregnant TS women as 2% based on analysis of 4 cases of AoD in pregnant TS
women and results of the survey conducted among assisted reproductive technology center
(76). Recent studies reviewed in this article present more optimistic data – only 7 cases of
AoD were described by 5 authors. In most of the studies the prevalence of high-risk
pregnancies was not established due to poor rate of cardiac screening before conception (Table 1.). Grewal et al. described 10 patients (15%) fulfilling the ASRM high-risk pregnancy criteria with observation of no adverse cardiovascular outcomes reported in this group (77). When analyzing the characteristics of pregnant TS women who were diagnosed with AoD (Table 2.), it can be seen that dilatation of aorta is not the factor necessary for the occurrence of AoD. Cauldwell et al. described 2 patients with AoD with normal aortic diameter (78). Patient number 2 (Table 2) described by Chevalier et al. had no cardiac disturbances despite mild aortic insufficiency described in preconceptional echocardiography, however the enlargement of aortic root (35 mm) was diagnosed in 6. month of pregnancy (79). Those findings show that careful cardiac care during pregnancy is necessary even when the pregnancy is not considered high-risk for cardiovascular events. Cabanes et al. recommend cardiac screening at the end of the first and the second trimester, and every month of the third trimester. The heart MRI should be performed in case of > 10% increase in aortic diameter. If the aortic dilatation is confirmed, patient should be referred to hospital with access to the team of specialists of medical-surgical cardiology, obstetrics and neonatal intensive care (57).

In conclusion, isolated heart defects should not be contraindication to fertility preservation. Vigilance and immediate reaction when there is a risk of cardiovascular complication is crucial while providing the health-care of pregnant TS woman.

5. Conclusions

Eligibility for FP techniques should be established based on multiple factors. Primarily, ovarian reserve markers and cardiovascular contraindications to pregnancy should be thoroughly analyzed prior to any intervention. Among them there are however, no unambiguous indicators disqualifying the patient from FP. Therefore, the decision should be
made weighing the risks of invasive FP techniques and ethical concerns connected with patient’s age, with the chance of successfully preserving the reproductive potential. More evidence is thus needed to properly assess those odds and introduce FP in patients with TS into the standard practice.

6. Declaration of interest, Funding and Acknowledgements

6.1 Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

6.2 Funding

This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

6.3 Author contribution statement

MW, JG, ZN and AG performed literature searches, analyzed the database and wrote the manuscript.
7. References


15. Hook EB, Warburton D. Turner syndrome revisited: review of new data supports the hypothesis that all viable 45,X cases are cryptic mosaics with a rescue cell line, implying an origin by mitotic loss. Human genetics. 2014 133 417–24.


17. Nadesapillai, J. van der Velden, D. Smeets, G. van de Zande, D. Braat, K. Fleischer,


22. Carpini S, Carvalho AB, de Lemos-Marini SHV, Guerra-Junior G, Maciel-Guerra AT. FSH may be a useful tool to allow early diagnosis of Turner syndrome. BMC endocrine disorders. 2018 18:8


34. von Wolff M, Roumet M, Stute P, Liebenthron J. Serum anti-Müllerian hormone (AMH) concentration has limited prognostic value for density of primordial and primary follicles, questioning it as an accurate parameter for the ovarian reserve. Maturitas. 2020 134 34–40.


60. Grynberg M, Poulain M, Sebag-Peyrelevade S, le Parco S, Fanchin R, Frydman N.


70. Fuchs MM, Attenhofer Jost C, Babovic-Vuksanovic D, Connolly HM, Egbe A. Long-Term Outcomes in Patients With Turner Syndrome: A 68-Year Follow-Up. Journal of...
the American Heart Association. 2019 8 1–6.


8. Figure legends

Figure 1. Flowchart for question 1.

Figure 2. Flow chart for question 2.

Figure 3. Flow chart for question 3.
Pubmed (27) & Embase (98) search (N=125)

Initial screening (N=125)

Assessment to eligibility (N=29)

Manual search of reference lists (N=5)

Studies included (N=34)
Pubmed (68) & Embase (180) search
(N=248)

Initial screening
(N=248)

Assessment to eligibility
(N=42)

Manual search of reference lists
(N=7)

Studies included
(N=35)
Pubmed search
(N=175)

Initial screening
(N=175)

Assessment to eligibility
(N=37)

Manual search of reference lists
(N=0)

Studies included
(N=17)
<table>
<thead>
<tr>
<th>Reference number</th>
<th>Journal</th>
<th>Year of publication</th>
<th>Type of study</th>
<th>Cases</th>
<th>Pregnanacies</th>
<th>Number of dissections</th>
<th>Prepregnancy cardiac screening</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calanchini M. et al. (80)</td>
<td><em>Fertility &amp; Sterility</em></td>
<td>2020</td>
<td>retrospective</td>
<td>156</td>
<td>32 (18 spontaneous, 7 OD with live birth, 7 OD with miscarriage)</td>
<td>4/131 nulliparous</td>
<td>0/25 pregnant with live borns</td>
</tr>
<tr>
<td>Greval J. et al. (77)</td>
<td><em>Heart</em></td>
<td>2021</td>
<td>retrospective</td>
<td>60</td>
<td>68 pregnancies in 60 women</td>
<td>0/68 nulliparous;</td>
<td>0/60 6 months postpartum</td>
</tr>
<tr>
<td>Kooijman S. et al. (81)</td>
<td><em>The American Journal of Cardiology</em></td>
<td>2021</td>
<td>retrospective</td>
<td>30</td>
<td>30</td>
<td>0/30</td>
<td>22/30</td>
</tr>
<tr>
<td>Cadoret F. et al. (82)</td>
<td><em>European Journal of Obstetrics &amp; Gynecology and Reproductive Biology</em></td>
<td>2018</td>
<td>retrospective</td>
<td>103</td>
<td>170: 35 spontaneous, 5 by means of intra-conjugal ART., 130 with OD.</td>
<td>0/103</td>
<td>49/62 (79%) after 2009 Vs 56/93 (60%) before 2009</td>
</tr>
<tr>
<td>Cauldwell M. et al. (78)</td>
<td><em>An International Journal of Obstetrics &amp; Gynaecology</em></td>
<td>2021</td>
<td>retrospective</td>
<td>84</td>
<td>127</td>
<td>2/84 (2.38%)</td>
<td>73/127 (57.4%)</td>
</tr>
<tr>
<td>Obata S. et al. (83)</td>
<td><em>Clinical Pediatric Endocrinology</em></td>
<td>2020</td>
<td>retrospective</td>
<td>20</td>
<td>20 (18 with live birth)</td>
<td>0/20</td>
<td>MRI of the aorta: 5/20 (25%) ECG: 13/20 (65.0%)</td>
</tr>
<tr>
<td>Hadnott T. N. et al. (84)</td>
<td><em>Fertility &amp; Sterility</em></td>
<td>2011</td>
<td>retrospective</td>
<td>10</td>
<td>10 (5 spontaneous)</td>
<td>0/10</td>
<td>0/10</td>
</tr>
<tr>
<td>Author(s)</td>
<td>Journal</td>
<td>Year</td>
<td>Study Type</td>
<td>Total</td>
<td>Pregnancies</td>
<td>Outcome</td>
<td></td>
</tr>
<tr>
<td>-----------</td>
<td>---------</td>
<td>------</td>
<td>------------</td>
<td>-------</td>
<td>-------------</td>
<td>---------</td>
<td></td>
</tr>
<tr>
<td>Bryman I. et al. (5)</td>
<td>Fertility &amp; Sterility</td>
<td>2011</td>
<td>retrospective</td>
<td>57</td>
<td>124</td>
<td>1/57 (1.75%)</td>
<td></td>
</tr>
<tr>
<td>Donadille B. et al. (4)</td>
<td>Fertility &amp; Sterility</td>
<td>2015</td>
<td>retrospective</td>
<td>480</td>
<td>52 in 27 women (spontaneous)</td>
<td>0/52</td>
<td>25/30 pregnancies</td>
</tr>
<tr>
<td>Mercadal B. A. (85)</td>
<td>Human Reproduction</td>
<td>2011</td>
<td>retrospective</td>
<td>23</td>
<td>18 (OD)</td>
<td>0/23</td>
<td>All</td>
</tr>
<tr>
<td>Doğer E. et al. (86)</td>
<td>Reproductive Biology and Endocrinology</td>
<td>2015</td>
<td>retrospective</td>
<td>22</td>
<td>23</td>
<td>no data</td>
<td>no data</td>
</tr>
<tr>
<td>Chevalier N. et al. (79)</td>
<td>The Journal of Clinical Endocrinology &amp; Metabolism</td>
<td>2011</td>
<td>retrospective</td>
<td>93</td>
<td>93</td>
<td>2/93 (2.2%)</td>
<td>56/93 (60.2%); echo: 31/93 (33.3%); thoracic MRI: 4/93 (4.3%); aortic diameter: 6/93 (6.4%)</td>
</tr>
<tr>
<td>Deligeorgiou E. et al. (87)</td>
<td>Journal of Obstetrics and Gynaecology</td>
<td>2016</td>
<td>retrospective</td>
<td>4</td>
<td>4</td>
<td>0/4</td>
<td>All</td>
</tr>
<tr>
<td>Hagman A. et al. (88)</td>
<td>Human Reproduction</td>
<td>2013</td>
<td>retrospective</td>
<td>110</td>
<td>122</td>
<td>1/110 (0.9%)</td>
<td>73/115 (63.5)</td>
</tr>
<tr>
<td>Hagman A. et al. (89)</td>
<td>The Journal of Clinical Endocrinology &amp; Metabolism</td>
<td>2011</td>
<td>retrospective</td>
<td>115</td>
<td>205</td>
<td>1/115 (0.87%)</td>
<td>no data</td>
</tr>
<tr>
<td>Metabolism</td>
<td>Bodri D. et al. (90)</td>
<td>Giles J et al. (91)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------------------------------------------</td>
<td>----------------------</td>
<td>---------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Human Reproduction</td>
<td>Fertility &amp; Sterility</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2005</td>
<td>2020</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>retrospective</td>
<td>retrospective</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>21</td>
<td>166</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>12</td>
<td>93</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0/12</td>
<td>0/93</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>All</td>
<td>All</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 1. Summary of the literature analyzed for question 3.
<table>
<thead>
<tr>
<th>Author</th>
<th>Case number</th>
<th>Age of AoD</th>
<th>Karyotype</th>
<th>Heart defect</th>
<th>ASI/aortic root diameter</th>
<th>Maternal outcomes</th>
<th>Fetal outcomes</th>
<th>Pregnancy week when AoD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cauldwell M. et al. (78)</td>
<td>1</td>
<td>no data</td>
<td>45,X</td>
<td>BAV</td>
<td>15</td>
<td>Survived</td>
<td>stillborn</td>
<td>OD</td>
</tr>
<tr>
<td>Cauldwell M. et al. (78)</td>
<td>2</td>
<td>no data</td>
<td>45,X</td>
<td>BAV</td>
<td>16</td>
<td>Died</td>
<td>no data</td>
<td>OD</td>
</tr>
<tr>
<td>Bryman I. et al. (5)</td>
<td>3</td>
<td>38</td>
<td>Y-chromosome fragment</td>
<td>CoA</td>
<td>no data</td>
<td>survived</td>
<td>no data</td>
<td>2nd SP 7 month</td>
</tr>
<tr>
<td>Chevalier N. et al. (79)</td>
<td>4</td>
<td>33</td>
<td>no data</td>
<td>BAV, aortic dilatation</td>
<td>39 mm</td>
<td>Died</td>
<td>no data</td>
<td>OD 38 week</td>
</tr>
<tr>
<td>Chevalier N. et al. (79)</td>
<td>5</td>
<td>33</td>
<td>no data</td>
<td>grade 1 aortic insufficiency; aortic dilatation</td>
<td>35 mm</td>
<td>Died</td>
<td>no data</td>
<td>OD 7 days after cesarian section</td>
</tr>
<tr>
<td>Hagman A. et al. (88)</td>
<td>6</td>
<td>28</td>
<td>mosaicism</td>
<td>healthy</td>
<td>no data</td>
<td>survived</td>
<td>no data</td>
<td>OD 20 days after delivery</td>
</tr>
<tr>
<td>Hagman A. et al. (89)</td>
<td>7</td>
<td>36</td>
<td>45,X in 46 cells and a Y mosaicism in four cells</td>
<td>no data</td>
<td>no data</td>
<td>survived</td>
<td>survived</td>
<td>2nd SP 32</td>
</tr>
</tbody>
</table>

Table 2. Characteristics of pregnant women with TS diagnosed with AoD. (AoD – dilatation of the aorta, CoA – coarctation of the aorta, BAV – bicuspid aortic valve)